Evidence map›Paper›PMID 41419605›Full record

ArticleLeukemia2026

Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.

Marietta Truger, Manja Meggendorfer, Wencke Walter, Stephan Hutter, Winfried Alsdorf, Gero Massenkeil, Uwe M Martens, Wolfgang Kern, Katharina Hörst, Constanze Kühn and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05046444 (Testing the Diagnostic Supremacy of Sequencing-only Approaches in Hematologic Malignancies), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05046444 recruitingnot on this map

Testing the Diagnostic Supremacy of Sequencing-only Approaches in Hematologic Malignancies: an Observational Trial

TypeobservationalSponsorMunich Leukemia LaboratoryRan2022 to 2026Enrolled100ConditionsLeukemia, Hematologic Malignancy, Rare Diseases, Refractory LeukemiaArmsNext Generation Sequencing
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marietta TrugerMLL Munich Leukemia Laboratory, Munich, Germany.
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-9038-3265
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-5083-9838
Stephan HutterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0003-2432-8898
Winfried AlsdorfUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Gero MassenkeilDepartment of Internal Medicine II, Klinikum Gütersloh, Gütersloh, Germany.
Uwe M MartensDepartment for Hematology and Oncology, SLK-Clinics Heilbronn GmbH, MOLIT Institute for Personalized Medicine, Heilbronn, Germany.ORCID 0000-0001-7999-4359
Wolfgang KernMLL Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-6452-2874
Katharina HörstMLL Munich Leukemia Laboratory, Munich, Germany.
Constanze KühnMLL Munich Leukemia Laboratory, Munich, Germany.
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Andreas HochhausDepartment of Hematology and Internal Oncology, Universitätsklinikum Jena, Jena, Germany.ORCID 0000-0003-0626-0834
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany. torsten.haferlach@mll.com.ORCID 0000-0003-0196-2837

Funding

Illumina MR-000125
6 · The paper itself

Abstract

In the rapidly evolving field of hematology, the diagnosis of leukemias and lymphomas poses major challenges, despite significant genetic advancements. Although established diagnostic methods comprise a multidisciplinary approach and are considered gold standard, in some cases they fall short in conclusively identifying hematological neoplasms. In this context, the current SIRIUS study (NCT05046444) delves into the potential of whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) to bridge diagnostic gaps. By analyzing 106 patients with an unclear diagnosis or clinical condition following gold standard diagnostics, our study demonstrates that WGS and WTS can uncover a broader range of somatic alterations, including rare single-nucleotide variants (SNVs), small copy number variations (CNVs), and aberrant gene expression patterns not detected by conventional diagnostics. WGS and WTS provided additional diagnostic insights in 25% of cases, suggesting their value not only in enhancing diagnostic accuracy but also in contributing to more informed prognostic assessments and personalized treatment strategies. Therefore, our study underscores the importance of integrating WGS and WTS into the diagnostic toolbox for hematological neoplasms. This approach promises not only to improve patient outcomes but also to do so in a manner that is both financially sustainable and ethically sound.

Indexed as

Biomarkers, TumorGenome, HumanHematologic NeoplasmsTranscriptomeWhole Genome SequencingAdultAgedDNA Copy Number VariationsExome SequencingFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPolymorphism, Single NucleotideBiomarkers, Tumor

Identifiers

PMID41419605
PMCPMC12789012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.